MYC and breast carcinoma: In a nutshell, treatment with either form of Omomyc switches off MYC targets and impacts on protumorigenic and prometastatic gene sets, downregulating cell-cycle progression, EMT, and genes related to breast cancer grade, and upregulating genes involved in tumor rejection, among many others.